Literature DB >> 1640303

Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis.

F Proulx1, J P Turgeon, G Delage, L Lafleur, L Chicoine.   

Abstract

We undertook a prospective, controlled study to evaluate the effect of trimethoprim-sulfamethoxazole in children with proven Escherichia coli O157:H7 enteritis on the duration fo symptoms, on fecal excretion of pathogen, and on the risk of progression to hemolytic-uremic syndrome. There was no statistically significant effect of treatment on progression of symptoms, fecal pathogen excretion, or the incidence of HUS (2/22 vs 4/25; p = 0.67). Our results suggest that a multicentric trial using rapid diagnostic methods to permit early randomization should be carried out.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640303     DOI: 10.1016/s0022-3476(05)81209-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  36 in total

1.  Escherichia coli infections and hemolytic-uremic syndrome.

Authors:  N Cimolai
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

3.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

Review 4.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

Review 5.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

6.  Control of enterohaemorrhagic Escherichia coli infection: the need for a network involving microbiological laboratories and clinical and public health institutions.

Authors:  H Karch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

7.  Antimicrobial susceptibility of Escherichia coli O157 and other enterohaemorrhagic Escherichia coli isolated in Italy.

Authors:  C Farina; A Goglio; G Conedera; F Minelli; A Caprioli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

Review 8.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02

Review 10.  Update on Escherichia coli O157:H7.

Authors:  J Mark Lawson
Journal:  Curr Gastroenterol Rep       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.